[go: up one dir, main page]

AU1339701A - Anti-cancer nucleic acid and protein targets - Google Patents

Anti-cancer nucleic acid and protein targets

Info

Publication number
AU1339701A
AU1339701A AU13397/01A AU1339701A AU1339701A AU 1339701 A AU1339701 A AU 1339701A AU 13397/01 A AU13397/01 A AU 13397/01A AU 1339701 A AU1339701 A AU 1339701A AU 1339701 A AU1339701 A AU 1339701A
Authority
AU
Australia
Prior art keywords
nucleic acid
protein targets
cancer nucleic
cancer
targets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13397/01A
Inventor
Joseph P. Brown
Glenna C Burmer
David Pritchard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeSpan BioSciences Inc
Original Assignee
LifeSpan BioSciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeSpan BioSciences Inc filed Critical LifeSpan BioSciences Inc
Publication of AU1339701A publication Critical patent/AU1339701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU13397/01A 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets Abandoned AU1339701A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16123299P 1999-10-22 1999-10-22
US60161232 1999-10-22
US69378300A 2000-10-19 2000-10-19
US09693783 2000-10-19
PCT/US2000/029126 WO2001030964A2 (en) 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets

Publications (1)

Publication Number Publication Date
AU1339701A true AU1339701A (en) 2001-05-08

Family

ID=26857637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13397/01A Abandoned AU1339701A (en) 1999-10-22 2000-10-20 Anti-cancer nucleic acid and protein targets

Country Status (2)

Country Link
AU (1) AU1339701A (en)
WO (1) WO2001030964A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002215689B2 (en) * 2000-12-11 2006-05-18 Biosceptre Pty Ltd P2Y purinergic receptor expression for identifying preneoplastic and neoplastic states
AU2002244112B2 (en) * 2001-02-21 2007-05-10 Novartis Vaccines And Diagnostics, Inc. TTK in diagnosis and as a therapeutic target in cancer
AU2007203399B2 (en) * 2001-02-21 2009-12-03 Novartis Vaccines And Diagnostics, Inc. TTK in diagnosis and as a therapeutic target in cancer

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
PT1360203E (en) 2001-01-17 2009-04-03 Intreat Pty Ltd Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
WO2002061432A2 (en) * 2001-02-01 2002-08-08 Lifespan Biosciences, Inc. Gpr22, a g protein-coupled receptor (gpcr) and compositions and methods related thereto
US7501242B2 (en) 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polynucleotide expression
WO2002099140A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US20050008643A1 (en) * 2001-06-27 2005-01-13 Ora Bernard Diagnostic methods and agents
NZ554740A (en) 2002-05-24 2009-01-31 Schering Corp Neutralizing human anti-IGFR antibody
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
US8415315B2 (en) * 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
WO2006060419A2 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
WO2006138696A2 (en) * 2005-06-17 2006-12-28 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
AU2007306924A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
BRPI0915367B8 (en) 2008-07-04 2021-05-25 Biosceptre International Ltd anti-p2x7 peptide
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
CN103702683B (en) 2011-07-01 2017-07-04 生物权威(澳大利亚)有限责任公司 Therapeutic alliance

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002215689B2 (en) * 2000-12-11 2006-05-18 Biosceptre Pty Ltd P2Y purinergic receptor expression for identifying preneoplastic and neoplastic states
AU2002244112B2 (en) * 2001-02-21 2007-05-10 Novartis Vaccines And Diagnostics, Inc. TTK in diagnosis and as a therapeutic target in cancer
AU2007203399B2 (en) * 2001-02-21 2009-12-03 Novartis Vaccines And Diagnostics, Inc. TTK in diagnosis and as a therapeutic target in cancer

Also Published As

Publication number Publication date
WO2001030964A2 (en) 2001-05-03
WO2001030964A3 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU1339701A (en) Anti-cancer nucleic acid and protein targets
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU2001292561A1 (en) Nucleic acids and polypeptides
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU5471600A (en) Variant tlr4 nucleic acid and uses thereof
AU6458400A (en) Nucleic acid, polypeptides, assays, therapeutic methods and means
AU5013200A (en) Target independent assay systems and methods
AU5245900A (en) Novel protein and dna thereof
AU5178999A (en) Nucleic acid delivery
AU7987800A (en) Anti-aging nucleic acid and protein targets
AU1891301A (en) Novel polypeptide and dna thereof
AU2001274566A1 (en) Novel protein and dna thereof
AU3511100A (en) Novel nucleic acids and polypeptides
AU1855001A (en) A new member of the pak protein family, nucleic acids and methods related to thesame
AU2136401A (en) P450rai-2 and related proteins
AU2153401A (en) Gene expression in biological conditions
AU2225401A (en) Novel protein and dna thereof
AU2002367841A1 (en) Bsnd nucleic acids and proteins
AU2001259240A1 (en) Novel stmst protein and nucleic acid mocecules and uses therefor
AU1690200A (en) Novel protein and dna thereof
AU2813700A (en) Protein assay
AU5494700A (en) Rna metabolism proteins
AU3364401A (en) Modified nucleic acids and their use
AU5447999A (en) Novel protein and dna thereof
AU2003265635A1 (en) Nphp nucleic acids and proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase